Применение Ковид-Глобулина В Терапии COVID-19

Arutyunov, A. G.; Avdeev, S. N.; Батюшин, М. М.; Боярков, Александр Валентинович; Bulanov, A. Yu.; Быкова, Екатерина Андреевна; Galstyan, Gagik R.; Никитин, И. Г.; Панкратова, Анастасия Андреевна; Разумихин, Михаил Вадимович; Салухов, В. В.; Tarlovskaya, E. I.; Fomina, Daria; Smolyanova, T. I.; Melnikov, E. S.; Саканян, Елена Ивановна

doi:10.30906/0869-2092-2022-85-3-13-20

Эксп. и клин. фармакол.

2022

DOI: 10.30906/0869-2092-2022-85-3-13-20

|View full text |Cite

Применение Ковид-Глобулина В Терапии COVID-19

A. G. Arutyunov¹,

S. N. Avdeev²,

М. М. Батюшин³

et al.

Abstract: Под эгидой Евразийской Ассоциации Терапевтов был организован Совет Экспертов по разработке критериев сроков назначения (день заболевания) КОВИД-глобулина, режима дозирования и фенотипа пациентов в зависимости от коморбидной патологии для оптимизации показаний и достижения максимальной эффективности вирус-нейтрализующей терапии. Необходимость создания данного Совета Экспертов заключается в отсутствии критериев, основанных на крупных доказательных исследованиях. Именно поэтому в состав рабочей группы входят эксп… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases

Igityan,

Burgasova,

Generalova

2024

Vrach

View full text Add to dashboard Cite

Human Specific Hyperimmune Globulins (HIG) are dosage forms of the concentrated purified protein fraction of immunoglobulin G against a specific viral or bacterial antigen. Effective and safe methods of the antibody’s purification makes possible to consider HIG as a preventive and curative agent, for the viral infections, against which there is no specific preventive or antiviral therapy, as well as bacterial infectious diseases due to increasing resistance to antibacterial drugs, especially in persons with immunodeficiencies.

show abstract

Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases

Igityan,

Burgasova,

Generalova

2024

Vrach

View full text Add to dashboard Cite

show abstract

Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations

Smolyanova¹,

Николаева

Vyaznikova

et al. 2022

Biological Products. Prevention, Diagnosis, Treatment

View full text Add to dashboard Cite

The development of COVID-globulin, a COVID-19-specific human immunoglobulin preparation, involved choosing a method to quantify antibodies to SARS-CoV-2. Antibody titre determination by virus neutralisation (VN) is labour-intensive and unsuitable for large-scale application. To enable routine testing, it was necessary to develop a less demanding method; the enzyme-linked immunosorbent assay (ELISA) was the most appropriate of solutions. The lack of international and industry reference standards (RS) prompted the preparation and certification of an RS for COVID-globulin potency control.The aim of the study was to examine the possibility of substituting ELISA for VN and to develop an RS for SARS-CoV-2 antibody quantification in immunoglobulin preparations.Materials and methods: the authors used commercial ELISA kits by several manufacturers, COVID-globulin by Microgen (48 batches), and human plasma samples from multiple sources (1499 samples). The tests were performed by VN, ELISA, and chemiluminescent microparticle immunoassay.Results: the authors validated an ELISA method for SARS-CoV-2 antibody quantification with the selected reagent kits by the National Medical Research Center for Hematology (NMRC for Hematology) and Euroimmun AG. The authors demonstrated the possibility of using ELISA instead of VN (with a correlation coefficient of more than 0.9). They developed and characterised an in-house RS for SARS-CoV-2 antibody content in human immunoglobulin preparations. The RS was certified in newly introduced anti-COVID units (ACU) and in international binding antibody units (BAU) using the World Health Organisation (WHO) international reference panel (NIBSC code: 20/268). The RS's potency was measured in terms of its neutralising activity in ACU (320 ACU/mL) and BAU (2234.8 BAU/mL). The authors established the relationship between ACU and BAU units. For the selected ELISA reagent kits, the conversion factors were 6.4 (NMRC for Hematology) and 7.0 (Euroimmun AG).Conclusions: the ELISA method for SARS-CoV-2 antibody quantification and the RS for SARS-CoV-2 antibody content can be applied to determine the potency of human anti-COVID-19 immunoglobulins.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Применение Ковид-Глобулина В Терапии COVID-19

Cited by 2 publications

References 0 publications

Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases

Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases

Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations

Contact Info

Product

Resources

About